GeoVax Labs (GOVX) files 8-K noting Q3 2025 results release

Rhea-AI Filing Summary

GeoVax Labs, Inc. filed a current report to note that it released a press release covering its operating results for the quarter ended September 30, 2025. The company states that this press release, dated November 13, 2025, is furnished as Exhibit 99.1 to the report.

The filing also includes standard forward-looking statement language, explaining that projections and expectations are subject to risks and uncertainties, and that actual results may differ from current views. The report is signed on behalf of GeoVax Labs by its Chief Financial Officer, Mark W. Reynolds.

false 0000832489 0000832489 2025-11-13 2025-11-13

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  November 13, 2025

GEOVAX LABS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39563		87-0455038
(State or other jurisdiction of incorporation or organization)		(Commission File No.)		(IRS Employee Identification No.)

1900 Lake Park Drive, Suite 380

Smyrna, Georgia 30080

(Address of principal executive offices) (Zip code)

(678) 384-7220

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	GOVX	The Nasdaq Capital Market

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

Forward-Looking Statements

This Current Report on Form 8-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. When used in the Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward looking statements.  Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Company’s industry, operations and results of operations and any businesses that may be acquired by the Company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Except as required by law, the Company does not undertake to update its forward-looking statements.

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2025, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d)     Exhibits

Exhibit No.	Description
99.1	Press Release dated November 13, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 13, 2025

	GEOVAX LABS, INC.
	By:	/s/ Mark W. Reynolds
		Mark W. Reynolds
		Chief Financial Officer

3

FAQ

What did GeoVax Labs (GOVX) report in this 8-K filing?

The company reported that it issued a press release detailing its results of operations for the quarter ended September 30, 2025, which is attached as Exhibit 99.1.

Which period’s results are referenced by GeoVax Labs (GOVX) in this filing?

The filing references GeoVax Labs’ results of operations for the quarter ended September 30, 2025.

What exhibit is included with GeoVax Labs’ (GOVX) 8-K?

The filing includes Exhibit 99.1, a press release dated November 13, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the GeoVax Labs (GOVX) 8-K report?

The report was signed on behalf of GeoVax Labs, Inc. by Mark W. Reynolds, the company’s Chief Financial Officer.

Does the GeoVax Labs (GOVX) 8-K contain forward-looking statements?

Yes, the filing includes a section explaining that it contains forward-looking statements based on management’s beliefs and assumptions, and notes that actual results may differ due to various risks and uncertainties.

On what date did GeoVax Labs (GOVX) issue the referenced press release?

GeoVax Labs issued the referenced press release on November 13, 2025.